

Hampig Raphael Kourie

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3593834/hampig-raphael-kourie-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

782
citations

14
h-index

25
g-index

111
ext. papers

1,033
ext. citations

3.2
avg, IF

5.1
L-index

#	Paper	IF	Citations
69	Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 150, 102972	7	111
68	Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. <i>International Journal of Womens Health</i> , 2019 , 11, 431-437	2.8	61
67	New developments in the management of head and neck cancer - impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 295-303	2.9	44
66	Anal cancer treatment: current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2294-302	5.6	39
65	Road map for pain management in pancreatic cancer: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 599-606	3.4	33
64	Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. <i>Canadian Journal of Ophthalmology</i> , 2014 , 49, 450-7	1.4	28
63	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10124-10130	5.6	19
62	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019 , 11, 1409-1422	3.8	17
61	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. <i>Immunotherapy</i> , 2017 , 9, 647-657	3.8	15
60	Optimum chemotherapy in the management of metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2352-7	5.6	15
59	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016 , 34, 794-796	4.3	14
58	Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 745-750	3.4	14
57	Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. <i>Journal of Medical Case Reports</i> , 2017 , 11, 303	1.2	13
56	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. <i>Future Oncology</i> , 2019 , 15, 533-541	3.6	12
55	EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. <i>Cancer Epidemiology</i> , 2015 , 39, 1099-102	2.8	11
54	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. <i>Future Oncology</i> , 2019 , 15, 1505-1524	3.6	10
53	Optimum chemotherapy for the management of advanced biliary tract cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4121-5	5.6	9

52	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 145-150	2.5	9
51	Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 2679-81	1.7	9
50	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017 , 10, 3363-3372	4.4	8
49	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. <i>Journal of Bone Oncology</i> , 2015 , 4, 77-9	4.5	8
48	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020 , 21, 221-230.	6	7
47	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 297-304	3.4	7
46	Ocular and orbital side effects of ALK inhibitors: a review article. <i>Future Oncology</i> , 2019 , 15, 1939-1945	3.6	6
45	Physical long-term side-effects in young adult cancer survivors: germ cell tumors model. <i>Current Opinion in Oncology</i> , 2017 , 29, 229-234	4.2	5
44	Acute myeloid leukemia transformed to a targetable disease. <i>Future Oncology</i> , 2020 , 16, 961-972	3.6	5
43	Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy. <i>Case Reports in Ophthalmological Medicine</i> , 2015 , 2015, 142408	0.7	5
42	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103169	7	5
41	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , 2018 , 14, 2097-2102	3.6	4
40	Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience. <i>Bulletin Du Cancer</i> , 2020 , 107, 738-740	2.4	4
39	Molecular profiling of basal cell carcinomas in young patients. <i>BMC Medical Genomics</i> , 2021 , 14, 187	3.7	4
38	Skin adverse events in recently approved targeted therapies in solid malignancies. <i>Future Oncology</i> , 2019 , 15, 331-343	3.6	3
37	Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e23-4	2.4	3
36	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020 , 21, 721-727	2.6	3
35	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , 2018 , 14, 829-835	3.6	3

34	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3515-3515	2.2	3
33	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 425-428	2.5	3
32	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018 , 105, 857-861	2.4	3
31	EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18506-e18506	2.2	2
30	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 3294-8	1.4	2
29	Will advanced cholangiocarcinoma become a targetable malignancy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103233	7	2
28	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017 , 13, 1097-1103	3.6	1
27	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , 2020 , 9, CNS55	4	1
26	A rare case of acute myeloid leukemia with t(12;19)(q13;q13). <i>Leukemia Research Reports</i> , 2020 , 14, 100216	2.6	1
25	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017 , 13, 1999-2006	3.6	1
24	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 105-111	1	1
23	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2021 ,	3.8	1
22	Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 5899-902	1.7	1
21	YouTube as a source of information on breast cancer in the Arab world. <i>Supportive Care in Cancer</i> , 2021 , 29, 8009-8017	3.9	1
20	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021 , 13, 953-964	3.8	1
19	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021 , 13, 1053-1065	3.8	1
18	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. <i>Colorectal Cancer</i> , 2016 , 5, 91-93	0.8	0
17	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.. <i>JCO Global Oncology</i> , 2022 , 8, e2100153	3.7	0

16	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. <i>Pharmacogenomics</i> , 2021 , 22, 1237-1250	2.6	o
15	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 168, 103524	7	o
14	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021 , 48, 100782	11.1	o
13	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021 , 22, 791-803	8.3	o
12	The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon. <i>Complementary Therapies in Medicine</i> , 2020 , 53, 102534	3.5	
11	Knowledge and behavior of Lebanese parents regarding melanoma prevention in public and private school children.. <i>Melanoma Management</i> , 2021 , 8, MMT59	2.1	
10	Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13045-e13045	2.2	
9	Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13544-e13544	2.2	
8	Outcome of breast cancer screening: a Lebanese single institution experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 9471-3	1.7	
7	Efficacy and tolerability of second-line intra-arterial 5FU or mitomycin C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15061-e15061	2.2	
6	Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. <i>Pharmacogenomics</i> , 2020 , 21, 957-962	2.6	
5	Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?. <i>Pharmacogenomics</i> , 2021 , 22, 619-628	2.6	
4	Seizures in cancer patients: a vast spectrum of etiologies. <i>Future Neurology</i> , 2019 , 14, FNL30	1.5	
3	In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. <i>Future Oncology</i> , 2021 , 17, 11-12	3.6	
2	An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. <i>Leukemia Research Reports</i> , 2021 , 15, 100245	0.6	
1	Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?. <i>Pharmacogenomics</i> , 2022 , 23, 487-492	2.6	